Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma

被引：26
作者：
Lu, Jun [1 ,2 ,3 ]
Wood, David [1 ]
Ingley, Evan [2 ,3 ,4 ]
Koks, Sulev [5 ,6 ]
Wong, Daniel [7 ]
机构：
[1] Univ Western Australia, Fac Hlth & Med Sci, Med Sch, Perth, WA 6009, Australia
[2] Univ Western Australia, Harry Perkins Inst Med Res, Cell Signalling Grp, Perth, WA 6009, Australia
[3] Univ Western Australia, Ctr Med Res, Perth, WA 6009, Australia
[4] Murdoch Univ, Coll Sci Hlth Engn & Educ, Discipline Med Mol & Forens Sci, Perth, WA 6009, Australia
[5] Perron Inst Neurol & Translat Sci, Perth, WA 6009, Australia
[6] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Perth, WA 6009, Australia
[7] QEII Med Ctr, Anat Pathol, Perth, WA 6009, Australia
来源：
MOLECULAR BIOLOGY REPORTS | 2021年 / 48卷 / 04期
关键词：
Well-differentiated liposarcoma; Dedifferentiated liposarcoma; MDM2; amplification; Genomic mutation; Cell signalling; SOFT-TISSUE TUMORS; AMPLIFICATION LEVELS; PHASE-I; CDK4; AMPLIFICATION; JUN AMPLIFICATION; P53; PATHWAY; MDM2; EXPRESSION; GENE; ACTIVATION;
D O I：
10.1007/s11033-021-06362-5
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Well-differentiated liposarcoma (WDLPS) is the most frequent subtype of liposarcoma and may transform into dedifferentiated liposarcoma (DDLPS) which is a more aggressive subtype. Retroperitoneal lesions of WDLPS/DDLPS tend to recur repeatedly due to incomplete resections, and adjuvant chemotherapy and radiotherapy have little effect on patient survival. Consequently, identifying therapeutic targets and developing targeted drugs is critical for improving the outcome of WDLPS/DDLPS patients. In this review, we summarised the mutational landscape of WDLPS/DDLPS from recent studies focusing on potential oncogenic drivers and the development of molecular targeted drugs for DDLPS. Due to the limited number of studies on the molecular networks driving WDLPS to DDLPS development, we looked at other dedifferentiation-related tumours to identify potential parallel mechanisms that could be involved in the dedifferentiation process generating DDLPS.
引用
收藏
页码：3637 / 3647
页数：11
相关论文
共 110 条
  • [1] Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours
    Aleixo, P. B.
    Hartmann, A. A.
    Menezes, I. C.
    Meurer, R. T.
    Oliveira, A. M.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (12) : 1127 - 1135
  • [2] Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
    Amin-Mansour, Ali
    George, Suzanne
    Sioletic, Stefano
    Carter, Scott L.
    Rosenberg, Mara
    Taylor-Weiner, Amaro
    Stewart, Chip
    Chevalier, Aaron
    Seepo, Sara
    Tracy, Adam
    Getz, Gad
    Hornick, Jason L.
    Nucci, Marisa R.
    Quade, Bradley
    Demetri, George D.
    Raut, Chandrajit P.
    Garraway, Levi A.
    Van Allen, Eliezer M.
    Wagner, Andrew J.
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (16) : 5135 - 5142
  • [3] Frequent amplification of receptor tyrosine kinase genes in well-differentiated/dedifferentiated liposarcoma
    Asano, Naofumi
    Yoshida, Akihiko
    Mitani, Sachiyo
    Kobayashi, Eisuke
    Shiotani, Bunsyo
    Komiyama, Motokiyo
    Fujimoto, Hiroyuki
    Chuman, Hirokazu
    Morioka, Hideo
    Matsumoto, Morio
    Nakamura, Masaya
    Kubo, Takashi
    Kato, Mamoru
    Kohno, Takashi
    Kawai, Akira
    Kondo, Tadashi
    Ichikawa, Hitoshi
    [J]. ONCOTARGET, 2017, 8 (08) : 12941 - 12952
  • [4] Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
    Barretina, Jordi
    Taylor, Barry S.
    Banerji, Shantanu
    Ramos, Alexis H.
    Lagos-Quintana, Mariana
    DeCarolis, Penelope L.
    Shah, Kinjal
    Socci, Nicholas D.
    Weir, Barbara A.
    Ho, Alan
    Chiang, Derek Y.
    Reva, Boris
    Mermel, Craig H.
    Getz, Gad
    Antipin, Yevgenyi
    Beroukhim, Rameen
    Major, John E.
    Hatton, Charles
    Nicoletti, Richard
    Hanna, Megan
    Sharpe, Ted
    Fennell, Tim J.
    Cibulskis, Kristian
    Onofrio, Robert C.
    Saito, Tsuyoshi
    Shukla, Neerav
    Lau, Christopher
    Nelander, Sven
    Silver, Serena J.
    Sougnez, Carrie
    Viale, Agnes
    Winckler, Wendy
    Maki, Robert G.
    Garraway, Levi A.
    Lash, Alex
    Greulich, Heidi
    Root, David E.
    Sellers, William R.
    Schwartz, Gary K.
    Antonescu, Cristina R.
    Lander, Eric S.
    Varmus, Harold E.
    Ladanyi, Marc
    Sander, Chris
    Meyerson, Matthew
    Singer, Samuel
    [J]. NATURE GENETICS, 2010, 42 (08) : 715 - U103
  • [5] A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).
    Bauer, Todd Michael
    Gounder, Mrinal M.
    Weise, Amy M.
    Schwartz, Gary K.
    Carvajal, Richard D.
    Kumar, Prasanna
    Zernovak, Oleg
    Beck, Alida
    Doyle, Jana
    Mendell-Harary, Jeanne
    Kochan, Jarema Peter
    Chen, Shuquan
    LoRusso, Patricia
    Tap, William D.
    Somaiah, Neeta
    Hyman, David Michael
    Meric-Bernstam, Funda
    Hong, David S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin
    Beird, Hannah C.
    Wu, Chia-Chin
    Ingram, Davis R.
    Wang, Wei-Lien
    Alimohamed, Asrar
    Gumbs, Curtis
    Little, Latasha
    Song, Xingzhi
    Feig, Barry W.
    Roland, Christina L.
    Zhang, Jianhua
    Benjamin, Robert S.
    Hwu, Patrick
    Lazar, Alexander J.
    Futreal, P. Andrew
    Somaiah, Neeta
    [J]. COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2018, 4 (02):
  • [7] Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice
    Bi, Pengpeng
    Yue, Feng
    Karki, Anju
    Castro, Beatriz
    Wirbisky, Sara E.
    Wang, Chao
    Durkes, Abigail
    Elzey, Bennett D.
    Andrisani, Ourania M.
    Bidwell, Christopher A.
    Freeman, Jennifer L.
    Konieczny, Stephen F.
    Kuang, Shihuan
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2016, 213 (10) : 2019 - 2037
  • [8] Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma
    Bill, Kate Lynn J.
    Seligson, Nathan D.
    Hays, John L.
    Awasthi, Achal
    Demoret, Bryce
    Stets, Colin W.
    Duggan, Megan C.
    Bupathi, Manojkumar
    Brock, Guy N.
    Millis, Sherri Z.
    Shakya, Reena
    Timmers, Cynthia D.
    Wakely, Paul E., Jr.
    Pollock, Raphael E.
    Chen, James L.
    [J]. ONCOLOGIST, 2019, 24 (07) : 989 - 996
  • [9] SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
    Bill, Kate Lynn J.
    Garnett, Jeannine
    Meaux, Isabelle
    Ma, XiaoYen
    Creighton, Chad J.
    Bolshakov, Svetlana
    Barriere, Cedric
    Debussche, Laurent
    Lazar, Alexander J.
    Prudner, Bethany C.
    Casadei, Lucia
    Braggio, Danielle
    Lopez, Gonzalo
    Zewdu, Abbie
    Bid, Hemant
    Lev, Dina
    Pollock, Raphael E.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1150 - 1160
  • [10] MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes -: A comparative analysis of 559 soft tissue neoplasms with genetic data
    Binh, MBN
    Sastre-Garau, X
    Guillou, L
    de Pinieux, G
    Terrier, P
    Lagacé, R
    Aurias, A
    Hostein, I
    Coindre, JM
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (10) : 1340 - 1347
12345678910